Product Description
TOP1288, the first in a new class of agents called narrow spectrum protein kinase inhibitors (NSKIs), is being developed as a novel, non-absorbed treatment for ulcerative colitis (UC).
Mechanisms of Action: NSK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Rectal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Topivert Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2016-000390-20 | P2 |
Completed |
Colitis, Ulcerative |
2017-06-28 |
|
TOP2 | P2 |
Completed |
Colitis, Ulcerative |
2017-06-28 |
|
TOP1288-TV-03 | P1 |
Completed |
Colitis, Ulcerative |
2017-06-02 |
22% |
TV-01 | P1 |
Completed |
Colitis, Ulcerative |
2016-07-01 |